Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Jun 1;11(6):636-643.
doi: 10.1001/jamaoncol.2025.0756.

Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury

Shruti Gupta  1   2   3 , Ilya G Glezerman  4 , Jamie S Hirsch  5   6   7 , Api Chewcharat  1 , Sophia L Wells  1 , Jessica L Ortega  1 , Marta Pirovano  2 , Raphael Kim  8 , Kevin L Chen  8 , Kenar D Jhaveri  5   6 , Valda D Page  9 , Matthew H Abramson  4   10 , Anip Bansal  11 , Avisek Ghimire  12 , Melanie S Joy  12 , Ala Abudayyeh  9 , David E Leaf  1   3
Affiliations
Multicenter Study

Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury

Shruti Gupta et al. JAMA Oncol. .

Abstract

Importance: Cisplatin-associated acute kidney injury (CP-AKI) is a frequent complication of cisplatin chemotherapy and is associated with considerable morbidity and mortality. Prophylactic administration of intravenous (IV) magnesium attenuates CP-AKI in animal models; however, its association with CP-AKI in humans has not been rigorously evaluated.

Objective: To evaluate the association of prophylactic IV magnesium administration with CP-AKI in patients with cancer undergoing cisplatin chemotherapy.

Design, settings, and participants: This multicenter study was conducted at 5 major cancer centers across the US and included adult patients with cancer who were treated with a first dose of IV cisplatin between 2006 to 2022. Data analyses were performed from February to December 2024.

Exposure: IV magnesium vs no IV magnesium receipt on the first day of cisplatin treatment.

Main outcomes and measures: Composite outcome of CP-AKI or death, with CP-AKI defined as a 2-fold or greater increase in serum creatinine levels from baseline or receipt of kidney replacement therapy within 14 days after first dose of IV cisplatin. Secondary outcomes were CP-AKI or death, defined using alternative definitions, as well as major adverse kidney events at 90 days. Inverse probability treatment weighting was used to estimate the association between IV magnesium receipt and CP-AKI. Models were adjusted for demographics, comorbidities, laboratory values, receipt of concurrent nephrotoxic anticancer therapies, site, year of cisplatin administration, and cisplatin dose.

Results: A total of 13 719 patients were included (median [IQR] age, 59 [49-67] years; 7817 male [57%]), of whom 3893 (28.4%) received IV magnesium on the first day of cisplatin chemotherapy. The median (IQR) dose of IV magnesium was 2 (1-2) g. CP-AKI or death occurred in 104 of 3893 patients (2.7%) who received IV magnesium, and in 520 of 9826 (5.3%) who did not (adjusted odds ratio, 0.80; 95% CI, 0.66-0.97). Results were similar across a number of sensitivity analyses and secondary outcomes, including major adverse kidney events at 90 days.

Conclusions and relevance: This multicenter cohort study found that patients with cancer who received prophylactic IV magnesium before initiating treatment with IV cisplatin had a lower risk of CP-AKI compared to those who did not receive magnesium. Randomized clinical trials are needed to confirm these findings.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Gupta reported fees from GlaxoSmithKline for scientific coordination; consulting fees from Secretome, Proletariat Therapeutics, Mersana Therapeutics, and Alexion; grants from BTG, AstraZeneca, Janssen, and Wong Foundation outside the submitted work. Dr Glezerman reported support from MSK (core grant P30 CA008748). Dr Hirsch reported personal fees from Boehringer Ingelheim outside the submitted work. Dr Jhaveri reported consulting fees from Calliditas, George Clinicals, Otsuka, Deciphera, PMV Pharma, and Novartis; contributions to UpToDate and Lexicomp outside the submitted work. Dr Leaf reported grants from BioPorto, BTG International, Metro International Biotech, Renibus Therapeutics, and Alexion Pharmaceuticals; consulting fees from Sidereal Therapeutics, Casma Therapeutics, MexBrain, Entrada Therapeutics, CardioRenal, and Alexion Pharmaceuticals outside the submitted work. No other disclosures were reported.

References

    1. Matsui M, Makimoto A, Chin M, et al. Magnesium supplementation therapy to prevent cisplatin-induced acute nephrotoxicity in pediatric cancer: a randomized phase-2 trial. Int J Clin Oncol. 2024;29(5):629-637. doi: 10.1007/s10147-024-02489-0 - DOI - PubMed
    1. Suppadungsuk S, Phitakwatchara W, Reungwetwattana T, et al. Preloading magnesium attenuates cisplatin-associated nephrotoxicity: pilot randomized controlled trial (PRAGMATIC study). ESMO Open. 2022;7(1):100351. doi: 10.1016/j.esmoop.2021.100351 - DOI - PMC - PubMed
    1. Matsui M, Saito Y, Yamaoka S, et al. Kidney-protective effect of magnesium supplementation in cisplatin-containing chemotherapy for pediatric cancer: a retrospective study. J Pediatr Hematol Oncol. 2018;40(5):379-381. doi: 10.1097/MPH.0000000000001159 - DOI - PubMed
    1. Kimura T, Ozawa T, Hanai N, et al. Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer. J Otolaryngol Head Neck Surg. 2018;47(1):10. doi: 10.1186/s40463-018-0261-3 - DOI - PMC - PubMed
    1. Solanki MH, Chatterjee PK, Gupta M, et al. Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation. Am J Physiol Renal Physiol. 2014;307(4):F369-F384. doi: 10.1152/ajprenal.00127.2014 - DOI - PMC - PubMed

Publication types